老百姓(603883):药品零售业务承压 区域深耕与新零售布局成效显著

Summary of Key Points Core Viewpoint - The company reported a decline in revenue and net profit for the first half of 2025, with a focus on expanding its store network and enhancing online sales capabilities to drive future growth [1][2]. Group 1: Financial Performance - In H1 2025, the company achieved revenue of 10.77 billion yuan, a year-over-year decrease of 1.5%, and a net profit attributable to shareholders of 400 million yuan, down 20.9% year-over-year [1]. - The gross margin for H1 2025 was 33.1%, a decline of 1.2 percentage points, attributed to the increased sales proportion of new retail business [1]. - The company’s Q2 2025 revenue was 5.34 billion yuan, with a net profit of 150 million yuan, reflecting a year-over-year decrease of 18.9% [1]. Group 2: Store Expansion and Online Sales - As of H1 2025, the company had a total of 15,385 stores nationwide, with a net increase of 108 stores, primarily driven by a net increase of 305 franchise stores [2]. - Online sales reached approximately 1.49 billion yuan in H1 2025, representing a year-over-year growth of 32% [2]. - The company’s O2O and B2C sales ranked fourth and third in the market, respectively, showcasing its competitive strength in the new retail sector [2]. Group 3: Brand Innovation and Product Strategy - The company continues to innovate its private label brands, focusing on optimizing product categories and enhancing cost-performance [3]. - In H1 2025, sales from self-owned brand stores (excluding DTP) amounted to 1.76 billion yuan, accounting for approximately 23% of total sales, an increase of 1.5 percentage points [3]. Group 4: Investment Outlook - Revenue projections for 2025-2027 are estimated at 22.43 billion, 23.71 billion, and 25.17 billion yuan, with corresponding growth rates of 0.3%, 5.7%, and 6.2% [4]. - The expected net profit for the same period is 690 million, 750 million, and 850 million yuan, with growth rates of 33.3%, 9.0%, and 12.5% [4].